ing decades. However, traditional and emerging risk factors for stroke in SSA have not been well characterized, thus limiting efforts at curbing its devastating toll. The Stroke Investigative Research and Education Network (SIREN) project is aimed at comprehensively evaluating the key environmental and genomic risk factors for stroke (and its subtypes) in SSA while simultaneously building capacities in phenomics,
Introduction
There is a rising epidemic of stroke in Sub-Saharan Africa (SSA) directly resulting from the epidemiologic transition [1] [2] [3] [4] . This epidemiologic transition is driven by an exploding but neglected burden of non-communicable diseases including vascular risk factors such as systemic arterial hypertension, diabetes mellitus, and dyslipidemia culminating in stroke [3, 4] . The WHO estimates indicate that death from stroke and disability adjusted life years lost to stroke are at least 7 times higher in low-and middle-income countries -mostly in Africa -than in high-income countries [5] . The age-standardized stroke incidence and prevalence rates in Africa with a current population of over 1 billion are up to 316 per 100,000 and up to 981 per 100,000 population respectively with a 3-year mortality rate of 84% [1, 4] . Furthermore, stroke affects a relatively younger age group and the productive workforce in developing than in developed economies [1, 6] and has been shown to exert its severest toll in the physical, psychoemotional, cognitive, and social domains [7] [8] [9] [10] [11] [12] [13] .
To tackle the burden of stroke and unravel the reasons for the escalating epidemic, there is an urgent need to determine the role played by environmental and genetic factors to the risk and outcomes of stroke and its subtypes in SSA. The traditional risk factors for stroke including hypertension, diabetes mellitus, cigarette smoking, sedentary lifestyle, unhealthy diet, excessive alcohol intake, dyslipidemia, and truncal obesity are predicted to be on the increase among African populations but their relative contributions to stroke predisposition have not been explicitly quantified. This is because considerable evidence from several observational studies shows a remarkable heterogeneity in the profile of risk factors, prevalence, incidence, types, subtypes, natural history, and outcome of stroke across different geographical locations and different ethnicities. For instance, significantly higher age-standardized stroke mortality rates have been reported among males than females in Ghana and Nigeria [14] . Furthermore, notable differences in prevalence and mortality from stroke were noted among rural Tanzanians compared with rural South Africans, plausibly due to differential exposures of lifestyle risk factors and health transitions in these 2 populations [15] . Again, data from the INTERSTROKE study [16] showed that while ischemic and hemorrhagic strokes accounted for 66 and 34% of strokes in Africa, these figures were 91 and 9% respectively in high-income countries. Thus, several questions remain unanswered regarding the true proportions, etiologic sub-types, risk factor profiles, and genetic underpinnings of ischemic and hemorrhagic stroke in SSA. Although stroke is a discrete phenotype, it is the clinical culmination of several complex and interacting biological processes; hence, any step towards lessening its burden and formulating successful tailored prevention programs in SSA will require a deep understanding of the relative contributions of its predisposing risk factors.
Thus far, the underlying risk factors for stroke in SSA have not been sufficiently characterized. In addition, there is a paucity of expertise, experience, and infrastructure for sustainable cutting-edge stroke research in SSA. To this end, the Systematic Investigation of Blacks with Stroke-Phenomics (SIBS-Phenomics), an arm of the Stroke Investigative Research and Education Network (SIREN) project, will involve several geographically dispersed and ethnically diverse sites in SSA countries of Ghana and Nigeria with the aim of properly evaluating the key risk factors for stroke (and its subtypes) in these countries. It is hoped that the outcome of this study will provide accurate and reliable stroke phenotypes for a subsequent genomic study (SIBS-Genomics) which aims to explore the genetic risk factors for stroke (and its subtypes).
The aim of this manuscript is to describe the protocol for the evaluation of risk factors and the clinical, etiological, and pathological types of stroke in the current largest study on stroke in SSA.
Methods
Specific Aims and Hypotheses SIREN has 4 broad objectives and underlying hypotheses: our first objective is to evaluate the qualitative and quantitative contributions of traditional and novel socio-demographic, clinical, and radiologic risk factors to stroke occurrence, type, and outcome among individuals of Black race in SSA. This will be done via a cross-national, multicentre case-control study. The underlying hypothesis for this sub-objective is that the distribution of pre-specified risk factors will contribute to differences in the occurrence, type, and outcome of stroke among individuals of Black race in SSA. Second, we propose to compare socio-demographic, clinical, and radiographic risk factors for stroke among individuals of Black race in SSA to cohorts of individuals of Black race in the United States. We hypothesize that differences in the pattern of socio-demographic, clinical, and radiographic risk factors may account for differences in stroke occurrence, type, and outcome between Blacks in SSA and Blacks in the United States. Third, we will survey and elucidate the knowledge, attitude, beliefs, and practices of individuals of Black race in SSA about stroke and its risk factors, performance of genetic testing, and participation in research studies. Our hypothesis for this sub-objective is that systematic community engagement using established qualitative research methodologies will result in information that can be used to educate and mobilize the community regarding the nature of stroke, role of genetic testing, and benefits of involvement in research studies. And fourth, our objective is to generate comprehensive and accurate phenomic data on stroke patients and controls that will assure reliable phenotyping for a concurrent genomics project (SIBSGenomics) focused on evaluating genetic risk factors for stroke (and its subtypes). This is underscored by the hypothesis that coordinated expertise and experience leveraged from seasoned investigators and resources within 2 ongoing NIH-funded stroke studies in SSA will facilitate reliable stroke phenotyping.
Study Design
SIBS-Phenomics will be based on a case-control study design where every case will be matched to a control based on demographics (age, sex, ethnicity) using inclusion and exclusion criteria shown in table 1 . Matching on these factors will minimize the potential confounding effect of these variables on the relationship between stroke and the main environmental and genetic risk factors. This matched case-control design is based on a risk-set sam- 
Sampling frame
All patients admitted to medical ward, neurology or neurosurgical ward, ICU, emergency room, or reviewed in an outpatient clinic in the participating centres fulfilling the case definition for stroke will be logged and invited to participate in the study. Those who meet the eligibility criteria and provide informed consent will be included in the study.
Controls will be primarily community-based, but hospital-based controls will also be accepted. Hospital-based controls may be attendants or relatives of another (non-stroke) patient, or patients admitted to the hospital or visiting the hospital for conditions or procedures not related to stroke or TIA. Each control will be matched for sex and age (±5 years). There will be at least a control (with or without CV risks) for every case recruited. Where there is a significant representation from multiple ethnic groups, controls will also be matched with cases based on ethnicity.
Inclusion criteria
Patients who meet the following criteria will be included in the study Persons, with no clinical evidence of stroke, with or without cardiovascular risk factors.
Patients attending/admitted to study centres with first stroke (see definition below); Within 8 days of current symptom onset or 'last seen without deficit'; CT or MRI is planned within 10 days of symptom onset (note: beyond 10 days, ischemic and hemorrhagic strokes may be difficult to distinguish with great certainty); Adult aged 18 years or older (younger age group: difficulties with obtaining consent).
Exclusion criteria
Patients who meet the following criteria will be excluded from the study
A known previous history of stroke; Current hospitalization for acute coronary syndrome/myocardial infarction; Unable to provide consent and no surrogate Available.
(1)
Patients unable to communicate because of severe stroke, aphasia, or dementia and without a valid surrogate respondent (spouse or first degree relative who has lived with patient within the last year); Extra-axial hemorrhage, tumor or brain abscess; Subarachnoid hemorrhage; Current hospitalization for coronary heart disease; Unable to provide consent and no surrogate available; A known previous history of stroke.
pling framework, where cases and controls are sampled from a cohort of Africans who meet the inclusion criteria. Subjects with known outcomes (cases and controls) are measured for past exposures to estimate the relative risk of 'disease' since direct estimation of absolute risk is difficult [17] . By exploiting the setup of risk sets, case-control designs have been suggested as efficient ways of studying the association between outcomes and exposure [18] [19] [20] .
Study Sites
Eight collaborating centres in Nigeria and Ghana will use a standardized and comprehensive protocol based on the design of the WHO-STEPS Stroke Surveillance [21] , INTERSTROKE [16] , and REGARDS [22] protocols with relevant adaptations/modifications (to reflect the uniqueness of the African people, culture, lifestyles and the environment). This will be used to accrue detailed demographic, clinical, psychosocial, and neuroimaging data from 3,000 stroke patients in comparison with 3,000 demographicallymatched controls. To ensure accurate phenotyping, the stroke patients will be evaluated in hospitals well equipped with neuroimaging (CT and/or MRI), vascular, and cardiac (ultrasonography, electrocardiography (ECG), ECHO) facilities, while control recruitment will be enhanced through community stroke awareness programs. At each site, a community engagement team will be constituted. This team will collaborate with the Community Advisory Board made up of community leaders, faith-based leaders and key opinion leaders, stroke survivors, public health leaders, to engage communities at churches, mosques, market places, community meetings -to give talks on stroke awareness. At these meetings, the objectives of SIREN will also be highlighted and an invitation given to interested community members to serve as 'community-based controls' after screening them to rule out stroke using an 8-item questionnaire for verifying stroke free status (QVSFS). Potential 'hospital-based controls' will be approached at out-patient clinics/in-patient settings by research assistants and stroke as a diagnosis ruled out using the 8-item QVSFS those without stroke will be recruited as controls as shown in table 1 .
There are 6 participating sites in Nigeria including the University College Hospital and the WFNR-Blossom Centre for Neurorehabilitation, Ibadan; Federal Medical Centre and Sacred Heart Hospital, Abeokuta; Aminu Kano Teaching Hospital, Kano; Ahmadu Bello University, Zaria, and 2 sites in Ghana namely KorleBu Teaching Hospital, Accra and Komfo Anokye Teaching Hospital, Kumasi ( fig. 1 and 2 ). The demographic characteristics and the participating hospitals/study sites are shown in table 2 . The participating study sites are predominantly tertiary teaching hospitals (where stroke cases can be adequately investigated) situated such that stroke referrals are received from urban, semi-urban, and rural communities. Our community engagement core will also ensure that stroke cases in rural areas get referred to tertiary centers involved in the study by increasing the awareness on stroke.
Evaluation of Cases and Controls
The SIBS questionnaires (cases and controls) (available on request) will be used to accrue basic demographic and lifestyle data including ethnicity and native language of the subjects and their parents, socioeconomic status, dietary patterns, routine physical activity, stress (validated INTERSTROKE instrument), depression, cigarette smoking, and alcohol use ( table 3 ) . Others are infections, exposure to internal and external pollution, and personal medical and drug history. Also, cardiovascular and anthropometric (e.g. waist-hip ratio and weight) measurements will be obtained. Hypertension will be based on blood pressure levels and will be classified in the traditional categories of awareness, treatment, and control. In addition, resistant hypertension will be determined based on blood pressure values and the number of hypertension medications. Diabetes mellitus and dyslipidemia will 77 be based on fasting glucose levels and/or HBA 1c and fasting lipid profile. A detailed neurologic evaluation will be conducted to assess neurologic deficits and determine stroke severity using the National Institute of Health Stroke Severity Score, Stroke Levity Scale [23] , modified-Rankin Scale, and modified Barthel's Index scores on admission and serially monitored until discharge. Data on the therapy the patient received will also be documented as well as complications arising during hospital admission and vital status at discharge of patient.
In addition, the following evaluations will be performed: brain neuroimaging (CT or MRI of brain), ECG and/or Holter monitoring, transthoracic and/or trans-oesophageal echocardiography (for all cases of ischemic stroke, mandatory for all suspected cardioembolic stroke), and carotid Doppler USS (for all cases of ischemic stroke, anterior circulation). Ischemic stroke will be typed clinically using the Oxford Community Stroke Project criteria [24] and etiological sub-types will be defined using the Trial of Org 10172 in Acute Stroke Treatment [25] and Atherosclerosis-small vessel disease-cardiac source-other [26] criteria ( fig. 3 ) . Intracerebral hemorrhage will be classified etiologically into structural, medication-related, amyloid angiopathy, systemic/other disease, hypertension and undetermined causes as proposed by Meretoja et al. [27] The annotation and image markup on ClearCanvas software which we developed for phenotyping stroke patients based on radiological, clinical, and laboratory features, will also capture the above information including volume and location of bleeds, which is important for this classification.
Radiologic typing of stroke will be carried out at 3 levels of adjudication: first by the site PI-neurologist/neuroradiologist; second by site PIs-neurologists/neuroradiologists from other sites for verification; third by a stroke phenotyping committee with all site PIs and neuroradiologists (for ambiguous cases) and by carrying out random checks on all classified cases.
The 8-item QVSFS [28] has been validated in a sub-study (manuscript in preparation) and will be used to ascertain stroke free status in control subjects. Socio-demographic, lifestyle, medical, and drug history as well as anthropometric and vascular risk factors will be evaluated in controls.
Follow-Up Strategy
Stroke survivors will be followed up at dedicated neurology out-patient clinics upon discharge from medical wards in the participating institutions. The schedule for follow-up is at months 1, 3, 6, 9, and 12-post discharge. At each of these visits, patients will be assessed for control of risk factors, presence or absence of functional neurologic deficits using scales outlined earlier and taken through a neuro-psychological battery including the Montreal Cognitive Assessment [29] and an assessment of the impact of stroke on the quality of life and cognitive domains using the Health-Related Quality of Life in Stroke Patients [12] . The overall strategy for recruitment and follow-up of SIREN protocol is depicted in figure 4 .
Blood Sampling Strategy
Thirty five millilitres of venous sample will be obtained from cases and controls for the following subsequent analyses: sera and plasma separation for novel and emerging biomarkers of stroke and also for buffy coat preparation for DNA extraction to be used in SIBS genomics. Refer to the online supplementary information (for all online suppl. material, see www.karger.com/doi/10.1159/ 000437372) for sample processing protocol.
Sample Size Estimation and Power Justification
Prevalence of stroke in Africa is up to 315 per 100,000 population [2] . Given the current prevalence and incidence rate of stroke in Africa, a sample size of 3,000 cases and 3,000 controls will pro- vide sufficient sample size for the intended study to get a power of at least 80% for detecting an effect size of odds ratio at least 1.4, allowing for several types of exposures (categorical, count, or continuous) and the interactions among these exposures. A conditional logistic regression model will be used for analysis with a binary response variable (stroke status) and discrete or continuous covariates. To detect a change in the response variable from a proportion at baseline of 10-14%, which corresponds to an odds ratio of 1.4; a total sample size of 6,000 (3,000 cases and 3,000 controls) will lead to at least 80% power at a 0.05 significance level. An R-squared of 20% [30] was assumed to account for covariate adjustment in the multiple logistic regression model. This sample size is sufficient to detect odds ratios of at least 1.4 or more in subgroup analysis, for instance, to test an interaction between sub-type of stroke and exposures. Thus, a sample size of 6,000 will be sufficient to detect a range of effect sizes accounting for missing data.
Statistical Analysis
We will assess the association between exposure variables (e.g. routine physical activity (yes/no), stress score (validated INTERSTROKE instrument), depression (yes/no), cigarette smoking (yes/no) and alcohol use (yes/no)) and case-control status using conditional logistic regression [31] with and without adjustment to potential confounders that are not used in the matching. The adjusted model will include selected covariates and their interactions depending on whether or not covariates are confounders, by whether they did not improve the model fit, or increased the standard error of the parameter estimate of the primary exposure. The final model will be assessed for collinearity and goodness of fit using residual analysis.
Calculation of Population Attributable Risks (PARs). We will calculate both attributable risk (AR) and PAR for each of the exposure variables listed in table 3 . For instance, we will calculate the risk attributable to a unit increase in the stress score in the cases compared to the controls. We will use a model-based regression approach [32] to calculate the adjusted AR. The standard error of the adjusted AR will be estimated using the delta method or using the bootstrap. This calculation will be useful to infer the association between stroke and these exposure variables. Given that the final results are going to be based on the adjusted AR regression model, there are not issues of multiple comparisons that arise for exposures with more than 2 categories. We will combine data from Africa (SIBS) and the United States (REGARDS) [22] and we will fit logistic regression models with the outcome case-control status as a dependent variable and, each of the common exposures in both studies as independent variables with an interaction term by study type. The interaction term will allow us to estimate and test whether the odds ratio estimates corresponding to the common exposure variables are the same between the 2 studies. We will use the Wald test [33] for this purpose.
Missing Data and Recall Bias. We will handle missing data using several techniques including multiple imputation and maximum likelihood [31, 34] using SAS System version 9.4 (Cary, N.C., Table 3 . Variables to be studied in the SIBS-Phenomics (adapted from the INTERSTROKE study) [10] 81 USA). We will use missing data methods suggested for matched case-control data with missing covariate [35] . We will also use imputation techniques such as multiple imputation [35] and midpoint imputation [36] if the missing data mechanism is missing at random. To deal with missing categorical variables, we will use latent class multiple imputation [34] . Likelihood techniques will be used if the missing mechanism deviates from missing at random. Missing data assumptions will be determined based on the understanding of the missing data mechanism and tests to determine whether the missing data depends on observed data and sensitivity analysis [34] will be performed. To enable the controls to represent the same population as the cases, and thus reduce sampling bias, matching will be used. Matching enhances power, given the smaller sample size. Recall bias is ameliorated as data used in this study will be collected routinely prior to the knowledge of case/ control definition.
Discussion
There are several innovative aspects to SIBS-Phenomics. First, SIBS-Phenomics will be the first cross-national and sub-regional investigation aimed at fully exploring the environmental factors that contribute to stroke in SSA. Second, SIBS-Phenomics will explore all risk factors for stroke: traditional (such as hypertension, dyslipidemia, smoking, among others -observed mostly among people of White race in developed countries), emerging (such as inflammation, infections, sleep habits among others identified in developed countries), and environmental (such as both traditions and lifestyle-unique to Black people in SSA). Third, SIBS-Phenomics, will for the first time compare stroke in Negros in SSA (in Ghana and Nigeria) with Americans of African ancestry participating in the REGARDS study [22] . Fourth, SIBSPhenomics will ensure community sensitization to facilitate early presentation of stroke cases to hospital, thereby greatly minimizing referral bias as well as recruitment of controls from the community. This community engagement core within SIBS-Phenomics will be the firstof-its kind, a public outreach engagement initiative to evaluate and address perceptions about stroke and genomics by patients, caregivers, and local leaders. Doing this will help promote better uptake of medical regimen, adherence, behavioural modification, and participation in research studies by at-risk persons and the communities at large. It will also facilitate dissemination of results, as well as research uptake and impact. Finally, SIBS-Phenomics will be part of a central strategy in SSA to create intra-continental collaborations and build infrastructure, skills and capacity for research into stroke and cerebral disorders.
This undertaking may be challenged by the following: first, the recruitment of stroke cases within the hospital setting would mean that potentially patients with severe stroke may be recruited excluding patients with less severe strokes and those who may seek alternative therapies for stroke outside of hospital settings. Our community engagement strategy is designed to eliminate this bias. Second, even though all participating sites have at least one CT or MRI scanner in place, these investigative tools may break down and could limit our ability to accurately identify the type of stroke. However, privately operated CT/MRI scanners are available at all sites and would be resorted to should the need arise. Third, the funding provided for evaluation of a case-control pair is inadequate to thoroughly investigate all stroke patients. However, prudent fund management will be undertaken such that patients who can afford some of the investigations will be encouraged to pay, while support from the study will be targeted for those who cannot afford to pay for investigations to ensure recruitment and inclusion of all eligible stroke subjects and controls. Finally, storage of samples may be challenged by inadequate electrical power supply, a challenge we have approached by procuring alternative power supply mechanisms including solar powered inverter systems for our freezers.
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